Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Goldman on the Impact of Liquid Biopsies in Lung Cancer

March 4th 2020

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

CYP2D6 Genotype Linked With Suboptimal Outcomes in Breast Cancer

March 4th 2020

Patients with breast cancer who are ultrarapid or poor CYP2D6 metabolizers of tamoxifen have a worse prognosis compared with normal metabolizers after receiving a standard dose of the drug, due, in part, to a higher incidence of treatment-related adverse events.

Biomarker-Driven NSCLC Paradigm Advances With Novel Agents, Liquid Biopsies

March 4th 2020

Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.

Dr. Lopategui on the Implications of Genomic Sequencing in Lung Cancer

March 4th 2020

Jean Lopategui, MD, associate professor of pathology and director of Translational Genomics and of the Molecular Genetics Pathology Fellowship at Cedars-Sinai, discusses the implications of genomic sequencing in lung cancer.

Upfront Liquid Biopsy Use Expands Reach of Genomic Testing in NSCLC

March 3rd 2020

Hatim Husain, MD, discusses the current state of liquid biopsy in non–small cell lung cancer.

First-in-Class ADC Expands Portfolio of Precision Therapies in Bladder Cancer

February 28th 2020

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLC

February 26th 2020

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI Cancers

February 26th 2020

Brian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.

Dr. Brahmer on Targeting Driver Mutations in NSCLC

February 26th 2020

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

Dr. Beltran on Use of ctDNA to Evaluate Treatment Resistance in Prostate Cancer

February 25th 2020

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Targeting TRAIL: A Long and Winding Road to Efficacy

February 25th 2020

Results from a first-in-human study into ABBV-621, a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist, highlight the potential of focusing on TRAIL.

Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC

February 25th 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Armstrong on AR-V7 as a Biomarker of Response to Taxane Chemotherapy in mCRPC

February 25th 2020

Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the potential of AR-V7 as a predictive biomarker of response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Expert: Raise the Bar for Diagnostic Tools in Oncology

February 24th 2020

Daniel F. Hayes, MD, discusses the potential of liquid biopsies in breast and other cancers and highlights some major challenges that keep these tests from wider use.

Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types

February 22nd 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Dr. Lazarides on CRM1 as a Potential Target in Osteosarcoma

February 22nd 2020

Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.

Dr. O'Reilly on Ongoing Trials With PARP Inhibitors in Pancreatic Cancer

February 22nd 2020

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses

Dr. Paulson on the Importance of Biomarker Testing in Oncology

February 22nd 2020

R. Steven Paulson, MD, discusses the importance of molecular testing in the era of precision medicine in oncology.

Precision Medicine Approaches Evolving With CDK4/6, PI3K Inhibitors in HR+ Breast Cancer

February 21st 2020

Sara Tolaney, MD, MPH, reflects on the encouraging findings observed with CDK4/6 inhibitors in combination with endocrine therapy in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.

Dr. Cercek on Targeted Strategies in BRAF-Mutant mCRC

February 21st 2020

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.